The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ARCHIVE
ARCHIVE
- Takeda Applies for Novel ARB Azilsartan in Japan
April 4, 2011
- ASKA Resumes Production, Shipment of Thyradin-S Tablets
April 4, 2011
- Daiichi Sankyo's Direct Xa Inhibitor Rixiana Recommended for Approval by PAC
April 4, 2011
- Damage at Fukushima Plant to Affect 3 Brands: Ajinomoto Pharm.
April 4, 2011
- Eisai Announces Approval of Halaven in Europe
April 4, 2011
- Daiichi Sankyo Resumes Production at Some Facilities
April 4, 2011
- Fingolimod Approved for MS in Europe: Novartis
April 4, 2011
- Shipments of Ensure to Resume in Late May: Abbott Japan
April 4, 2011
- CHMP to Assess Benefit-Risk Balance of Pioglitazone
April 4, 2011
- Gas Shortage Hurting Distribution in Tohoku: Wholesalers
March 28, 2011
- Higher Dosage Approved for Meropen: DSP
March 28, 2011
- Conditional Approval Recommended for Use of Epogin for Myocardial Infarction as Kohdo-iryo
March 28, 2011
- NEW PRODUCTS
March 28, 2011
- DSP to Collaborate with Kyoto Univ. in Cancer Field
March 28, 2011
- Sanko Junyaku to Market RDKK's Cobas h 232 Series from April
March 28, 2011
- Nippon Shinyaku Aims at Sales of ¥5.2 Bil. for Vidaza
March 28, 2011
- TS-1 Approved for Advanced Stomach Cancer in Europe: Taiho
March 28, 2011
- Daiichi Sankyo to Promote MEMARY Both in 1st Line Therapy and Combination
March 28, 2011
- Japanese Market for Antimicrobials to Contract to US$3 Bil. in 2019: Datamonitor
March 28, 2011
- Baxter's PREFLUCEL Approved in 13 EU Countries
March 28, 2011
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…